Cd34 ab81289

After dewaxing in xylene and rehydration in graded alcohols, tissue sections were boiled in citrate buffer, pre-incubated with H₂O₂, and blocked with rabbit or goat serum (DAKO, Glostrup, Denmark). Sections were then incubated with a primary antibody and then with an HRP-conjugated secondary antibody. Proteins of interest were visualized using diaminobenzidine before counterstaining with hematoxylin. Antibodies used were as following: LPCAT1 (16112–1-AP, Proteintech), PCNA (10205–2-AP, Proteintech), CD34 (ab81289, Abcam, Cambridge, MA, USA) and MMP9 (10375–2-AP, Proteintech).

The following primary antibodies were used: antibodies against MYOF (sc‐376879), Vinculin (sc‐73614) and MMP‐2 (sc‐53630) from Santa Cruz Biotechnology (Dallas, TX, USA); antibodies against Vimentin (ab92547), Twist1 (ab50581) and CD34 (ab81289) from Abcam (Cambridge, MA, USA); antibodies against phospho‐FAK (Y397) (AF3398) and β‐actin (T0022) from Affinity Biosciences (Shanghai, China); and antibody against E‐cadherin (#14472) from Cell Signaling Technology (Danvers, MA, USA). MMP‐2 inhibitor, SB‐3CT (S7430), was obtained from Selleck (Houston, TX, USA). 3‐(4,5‐dimethyl‐2‐thiazolyl)‐2,5‐diphenyl‐2 ‐H‐tetrazolium bromide (MTT) was purchased from Sigma‐Aldrich (St. Louis, MO, USA).